At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRFX PainReform
Closed 01-12 16:00:00 EST
0.8028
-0.0472
-5.55%
盘后0.8400
+0.0372+4.63%
19:59 EST
High0.9242Low0.7800Vol690.75K
Open0.8400D1 Closing0.8500Amplitude16.96%
Mkt Cap3.14MTradable Cap3.00MTotal Shares3.92M
T/O585.73KT/O Rate18.49%Tradable Shares3.74M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

PainReform Reports Positive Phase I Safety Data for OcuRing-K Ocular Drug Platform
TIPRANKS  ·  01-12 22:37
PainReform Reports Positive Phase I Safety Data for OcuRing-K Ocular Drug Platform
PainReform Ltd - Announces Safety Data for Ocuring™-K Development
THOMSON REUTERS  ·  01-12 22:04
PainReform Ltd - Announces Safety Data for Ocuring™-K Development
PainReform Ltd - Preclinical Studies Show Favorable Tolerability for Ocuring™-K
THOMSON REUTERS  ·  01-12 22:04
PainReform Ltd - Preclinical Studies Show Favorable Tolerability for Ocuring™-K
PainReform’s OcuRing-K Platform Shows Favorable Safety in Phase I Clinical Study
Reuters  ·  01-12 22:02
PainReform’s OcuRing-K Platform Shows Favorable Safety in Phase I Clinical Study
PainReform Ltd. held shareholder meeting
Reuters  ·  01-07
PainReform Ltd. held shareholder meeting
DeepSolar Launches Smart TDD to Boost Global Solar Asset Due Diligence
Reuters  ·  01-05
DeepSolar Launches Smart TDD to Boost Global Solar Asset Due Diligence
PainReform Confirms LayerBio Ocular Platform Can Deliver Multiple Drugs in Sustained-Release Form
Reuters  ·  2025-12-10
PainReform Confirms LayerBio Ocular Platform Can Deliver Multiple Drugs in Sustained-Release Form
BRIEF-Painreform Commences Development For Ocuring™-K Phase II Trial
Reuters  ·  2025-12-02
BRIEF-Painreform Commences Development For Ocuring™-K Phase II Trial
PainReform Advances Drop-Less OcuRing-K Therapy Toward Phase II Trial
Reuters  ·  2025-12-02
PainReform Advances Drop-Less OcuRing-K Therapy Toward Phase II Trial
PainReform Commences Development for Ocuring™-K Phase Ii Trial, Layerbio’s Drop-Less Sustained-Release Ocular Therapy
THOMSON REUTERS  ·  2025-12-02
PainReform Commences Development for Ocuring™-K Phase Ii Trial, Layerbio’s Drop-Less Sustained-Release Ocular Therapy
PainReform Ltd. Announces December 2025 Shareholders Meeting with Key Proposals
TIPRANKS  ·  2025-11-26
PainReform Ltd. Announces December 2025 Shareholders Meeting with Key Proposals
PainReform Ltd. Announces Date for Upcoming Annual General Meeting of Shareholders
Reuters  ·  2025-11-26
PainReform Ltd. Announces Date for Upcoming Annual General Meeting of Shareholders
PainReform’s DeepSolar advances development of AI-driven reporting engine
TIPRANKS  ·  2025-11-12
PainReform’s DeepSolar advances development of AI-driven reporting engine
DeepSolar Advances AI-Driven Reporting Engine for Solar Asset Analysis
Reuters  ·  2025-11-12
DeepSolar Advances AI-Driven Reporting Engine for Solar Asset Analysis
PainReform’s DeepSolar Advances with NVIDIA Connect and Pilot Projects
TIPRANKS  ·  2025-11-05
PainReform’s DeepSolar Advances with NVIDIA Connect and Pilot Projects
BRIEF-PainReform’s DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link’s “Watchlist Interview” and Announces Progress Toward Pilot Projects
Reuters  ·  2025-11-05
BRIEF-PainReform’s DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link’s “Watchlist Interview” and Announces Progress Toward Pilot Projects
PainReform’s Deepsolar, Developing “Deepsolar Predict” Within the Nvidia Connect Program, Featured in the Market Link’s “Watchlist Interview” and Announces Progress Toward Pilot Projects
THOMSON REUTERS  ·  2025-11-05
PainReform’s Deepsolar, Developing “Deepsolar Predict” Within the Nvidia Connect Program, Featured in the Market Link’s “Watchlist Interview” and Announces Progress Toward Pilot Projects
BRIEF-Painreform Provides Business Update For The Six Months Ended June 30, 2025
Reuters  ·  2025-10-01
BRIEF-Painreform Provides Business Update For The Six Months Ended June 30, 2025
PainReform Announces H1 2025 Financial Results and Board Change
TIPRANKS  ·  2025-10-01
PainReform Announces H1 2025 Financial Results and Board Change
PainReform Ltd. Reports Reduced Net Loss and Maintains Positive Working Capital for First Half of 2025
Reuters  ·  2025-10-01
PainReform Ltd. Reports Reduced Net Loss and Maintains Positive Working Capital for First Half of 2025

Introduction

Company Name.
PainReform
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Issue price:
--